GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Teladoc Health Inc (NYSE:TDOC) » Definitions » Return-on-Tangible-Equity

Teladoc Health (Teladoc Health) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Teladoc Health Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Teladoc Health's annualized net income for the quarter that ended in Dec. 2023 was $-116 Mil. Teladoc Health's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-466 Mil. Therefore, Teladoc Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Teladoc Health's Return-on-Tangible-Equity or its related term are showing as below:

TDOC's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.2
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Teladoc Health Return-on-Tangible-Equity Historical Data

The historical data trend for Teladoc Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teladoc Health Return-on-Tangible-Equity Chart

Teladoc Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -278.41 - - - -

Teladoc Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Teladoc Health's Return-on-Tangible-Equity

For the Health Information Services subindustry, Teladoc Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teladoc Health's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Teladoc Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Teladoc Health's Return-on-Tangible-Equity falls into.



Teladoc Health Return-on-Tangible-Equity Calculation

Teladoc Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-220.368/( (-602.21+-424.898 )/ 2 )
=-220.368/-513.554
=N/A %

Teladoc Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-115.56/( (-507.442+-424.898)/ 2 )
=-115.56/-466.17
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Teladoc Health  (NYSE:TDOC) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Teladoc Health Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Teladoc Health's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Teladoc Health (Teladoc Health) Business Description

Traded in Other Exchanges
Address
2 Manhattanville Road, Suite 203, Purchase, NY, USA, 10577
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Executives
Daniel Trencher officer: SVP Corporate Strategy 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Vidya Raman-tangella officer: Chief Medical Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Karen L Daniel director 2801 80TH STREET, KENOSHA WI 53141
Jason N Gorevic director, officer: President & CEO
Andrew Turitz officer: SVP - Business Development C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Stephany Verstraete officer: Chief Marketing Officer C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Adam C Vandervoort officer: Chief Legal Officer, Secretary 485 MADISON AVENUE, NEW YORK NY 10022
Mala Murthy officer: Chief Financial Officer C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Richard J Napolitano officer: Chief Accounting Officer MSCI INC., 7 WORLD TRADE CENTER, 250 GREENWICH STREET, 49TH FLOOR, NEW YORK NY 10007
Arnnon Geshuri officer: Chief Human Resources Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Laizer Kornwasser officer: PRESIDENT, ENTERPRISE GROWTH 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417
Michael Willem Waters officer: CHIEF OPERATING OFFICER 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Jason Eric Evans director 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Claus Torp Jensen officer: Chief Innovation Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Sandra L Fenwick director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577